SEC Company Response from CERAGENIX PHARMACEUTICALS, INC. (CIK 0001180743) — Jul 13, 2005

CERAGENIX PHARMACEUTICALS, INC. (CIK 0001180743)
Date: July 13, 2005 · CIK: 0001180743 · Accession: 0001047469-05-019347

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-125967

Date

July 15, 2005

Author

/s/ STEVEN S. PORTER

Form

CORRESP

Company

CERAGENIX PHARMACEUTICALS, INC. (CIK 0001180743)

Letter

VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Re:Ceragenix Pharmaceuticals, f/k/a OnSource Corporation Pre-Effective Amendment No. 1 to Registration Statement on Form SB-2 File No. 333-125967 Request for Acceleration of Effectiveness

Dear Mr. Belliston:

On behalf of Ceragenix Pharmaceuticals, Inc., f/k/a OnSource Corporation (the "Company"), and pursuant to Rule 461 of Regulation C under the Securities Act of 1933, as amended, the Company hereby requests an acceleration of the effective date of its Registration Statement on Form SB-2 so that it will become effective at 9:00 a.m., Eastern Time, on Friday, July 15, 2005, or as soon thereafter as may be practicable.

The Company acknowledges that:

•should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

•the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

•the Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Thank you very much for your consideration.

Sincerely,
/s/ STEVEN S. PORTER

Show Raw Text

CORRESP
1
filename1.htm

CERAGENIX PHARMACEUTICALS, INC.
1444 Wazee Street, Suite 210

Denver, Colorado 80202

Telephone
(720) 946-6440

Facsimile (303) 534-1860

July 13,
2005

VIA EDGAR AND FACSIMILE

Mr. Greg Belliston, Staff Attorney

United States Securities and Exchange Commission

450 Fifth Street, N.W., Mail Stop 6010

Washington, DC 20549

Re:Ceragenix Pharmaceuticals, f/k/a OnSource Corporation

Pre-Effective Amendment No. 1 to Registration Statement on Form SB-2

File No. 333-125967

Request for Acceleration of Effectiveness

Dear Mr. Belliston:

On
behalf of Ceragenix Pharmaceuticals, Inc., f/k/a OnSource Corporation (the "Company"), and pursuant to Rule 461 of Regulation C under the Securities Act of 1933,
as amended, the Company hereby requests an acceleration of the effective date of its Registration Statement on
Form SB-2 so that it will become effective at 9:00 a.m., Eastern Time, on Friday, July 15, 2005, or as soon thereafter as may be practicable.

The
Company acknowledges that:

•should
the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with
respect to the filing;

•the
action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full
responsibility for the adequacy and accuracy of the disclosure in the filing; and

•the
Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Thank
you very much for your consideration.

Sincerely,

/s/ STEVEN S. PORTER

Steven S. Porter

Chief Executive Officer

SecProbe.io